Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Central Hospital, Nancy, France.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT01375400
First received: June 16, 2011
Last updated: June 20, 2011
Last verified: June 2011

June 16, 2011
June 20, 2011
December 2010
July 2011   (final data collection date for primary outcome measure)
Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke [ Time Frame: 1 month ] [ Designated as safety issue: No ]
We study laboratory parameters of the first 300 mg oral dose of aspirin given, within 48 hours, after ischemic cerebral event. For all patients, two blood sampling are performed, the first, during the third hour after aspirin intake and the second during the twenty-fourth hour. Platelet reactivity is studied on the basis of serum thromboxane B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.
measure of platelet recovery within 24 hours after the first oral dose of aspirine given at hospital at the acute phase of ischemic stroke [ Time Frame: 1 month ] [ Designated as safety issue: No ]
We study laboratory parameters of the first 300 mg oral dose of aspirin given, within 48 hours, after ischemic cerebral event. For all patients, two blood sampling are performed, the first, during the third hour after aspirin intake and the second during the twenty-fourth hour.Platelet reactivity is studied on the basis of serum thromboxane (TX) B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.
Complete list of historical versions of study NCT01375400 on ClinicalTrials.gov Archive Site
Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated [ Time Frame: 1 month ] [ Designated as safety issue: No ]
For patients already treated with a daily dose of aspirin, a supplementary withdrawn was done before aspirin intake. Platelet reactivity was studied on the basis of serum thromboxane B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.
Measure of effect of the first oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated [ Time Frame: 1 month ] [ Designated as safety issue: No ]
For patients already treated with a daily dose of aspirin, a supplementary withdrawn was done before aspirin intake. Platelet reactivity is studied on the basis of serum thromboxane (TX) B2 levels and light transmission aggregometry after stimulation of platelet-rich plasma by acid arachidonic and collagen 2µg/ml reported to results with collagen 20 µg/ml.
Not Provided
Not Provided
 
Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.

Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic event.

The principal hypothesis is that platelet activity would be able to recover during this day and could lead to ischemic recurrences.

Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23 hours after. Photometric aggregometry are performed with arachidonic acid and collagen induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.

Not Provided
Interventional
Not Provided
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Ischemic Stroke
  • Drug: Aspirin
    Administration of 300 mg of aspirin, per os.
  • Biological: blood sample
    2 blood samples will be performed
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
Not Provided
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult men and women
  • Ischemic stroke less than 48 hours
  • Signed consent

Exclusion Criteria:

  • Danger to prescription of aspirin (haemorrhagic risk...)
  • Prescription of heparin or VKA
Both
18 Years and older
No
Contact: Sébastien Richard, MD 3 83 85 16 56 ext 0 33 s.richard@chu-nancy.fr
France
 
NCT01375400
Aspirin
No
Direction recherche et innovation CHU Nancy, CentralHNF
Central Hospital, Nancy, France
Not Provided
Not Provided
Central Hospital, Nancy, France
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP